Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

4.63
-0.1100-2.32%
Post-market: 4.630.00000.00%19:30 EDT
Volume:2.99M
Turnover:14.05M
Market Cap:1.51B
PE:-11.22
High:4.86
Open:4.80
Low:4.63
Close:4.74
52wk High:7.30
52wk Low:3.69
Shares:325.83M
Float Shares:233.00M
Volume Ratio:0.59
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:3.90
PE(LYR):-13.58

Loading ...

Taysha Gene Therapies Grants New Hires 384,000 RSUs, Options for 92,400 Shares Under Inducement Plan

Reuters
·
Yesterday

Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Yesterday

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Taysha Gene Therapies Highlights Phase 1/2 Reveal Trial Data for TSHA-102 in Rett Syndrome at Child Neurology Society Meeting

Reuters
·
Oct 01

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting Tsha-102 Rett Syndrome Clinical Program at the 55TH Child Neurology Society Annual Meeting

THOMSON REUTERS
·
Oct 01

Wolfe Research Initiates Taysha Gene Therapies at Outperform

MT Newswires Live
·
Sep 17

Taysha Gene Therapies initiated with an Outperform at Wolfe Research

TIPRANKS
·
Sep 17

Taysha Gene Therapies Grants New Hires 314,000 RSUs, 92,400 Options at $5.7 Strike

Reuters
·
Sep 04

Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 04

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 04

Taysha Gene Therapies Highlights TSHA-102 Rett Gene Therapy Path Toward BLA Submission in Corporate Presentation

Reuters
·
Sep 01

MeiraGTx Q2 Revenue Jumps on Reogen License Revenue

Reuters
·
Aug 13

Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations

Reuters
·
Aug 13

Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return

Simply Wall St.
·
Aug 13

Turn Therapeutics Q2 Net Loss Per Share Widens on Higher R&D Costs

Reuters
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

TIPRANKS
·
Aug 12

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 12

Taysha Falls on Wider-than-Expected Quarterly Loss

Reuters
·
Aug 12

Piper Sandler Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

TIPRANKS
·
Aug 12